Login
$MYGN
$5.57 -$0.09 (1.59%) Live

$MYGN 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation

2026 Employee, Director and Consultant Equity Incentive Plan

05 Nov 2026 8-K: Other Events

On November 2, 2026, Myriad Genetics, Inc. (the “Company”) detected unauthorized access within its information technology network environment. Upon discovery, the Company promptly initiated its incident response procedures to contain the...

04 Nov 2026 8-K: Results of Operations and Financial Condition

SALT LAKE CITY, November 4, 2026 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2026, and raised the mi...

20 Oct 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

______________________________________________________________________________

09 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

This Separation Agreement and Release of Claims (“Agreement”) is entered into by and between Myriad Genetics, Inc. (together with its subsidiaries, affiliates, successors and assigns, the “Company”) and Brian Donnelly (“Executive” and to...

16 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

SALT LAKE CITY, September 16, 2026 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been promoted to Executive Vice President - Commercial, ef...

30 Jul 2026 8-K: Results of Operations and Financial Condition

SALT LAKE CITY, July 30, 2026 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its second quarter ended June 30, 2026, new initiatives focused ...

23 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

On June 17, 2026, Daniel M. Skovronsky M.D., Ph.D., a member of the Board of Directors of Myriad Genetics, Inc. (the “Company”) notified the Company that he is resigning as a director, effective immediately. Dr. Skovronsky’s resignation ...

04 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Myriad Genetics, Inc. 2026 Employee, Director and Consultant Equity Incentive Plan, have the following meanings:

05 May 2026 8-K: Results of Operations and Financial Condition

SALT LAKE CITY, May 5, 2026 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its first quarter ended March 31, 2026, and reaffirmed its financi...

23 Feb 2026 8-K: Results of Operations and Financial Condition

SALT LAKE CITY, February 23, 2026 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its fourth quarter ended December 31, 2025, and reaffirmed i...

12 Jan 2026 8-K: Results of Operations and Financial Condition

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

03 Nov 2025 8-K: Results of Operations and Financial Condition

SALT LAKE CITY, November 3, 2025 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2025 and reaffirmed its...

07 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation

This Separation Agreement and Release of Claims (“Agreement”) is entered into by and between Myriad Genetics, Inc. (together with its subsidiaries, affiliates, successors and assigns, the “Company”) and Scott Leffler (“Executive” and tog...

03 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation

On September 29, 2025, Natalie Munk, the Senior Vice President, Chief Accounting Officer and principal accounting officer of Myriad Genetics, Inc.’s (the “Company”), provided notice of her resignation from the Company, effective on Octob...

18 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation

SALT LAKE CITY, August 18, 2025 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, ...

05 Aug 2025 8-K: Results of Operations and Financial Condition

SALT LAKE CITY, August 5, 2025 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its second quarter ended June 30, 2025 and updated its financia...

31 Jul 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

SECTION 4.4 Payments, Computations; Proceeds of Collateral, Etc 40

05 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Myriad Genetics, Inc. 2017 Employee, Director and Consultant Equity Incentive Plan, as amended, have the following meanings:

06 May 2025 8-K: Results of Operations and Financial Condition

SALT LAKE CITY, May 6, 2025 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its first quarter ended March 31, 2025 and updated its previously ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support